Table 2.
Eligibility criteria for PrEPX Study.
| Gay, bisexual and transgender people | Heterosexual and transgender people | People who inject drugs | |
|---|---|---|---|
| Predicted risk of the study participant in the next 3 months | Likely to have multiple events of condomless anal intercourse (CLAI), with or without sharing intravenous drug use equipment | Likely to have multiple events of condomless anal or vaginal intercourse, with or without sharing intravenous drug use equipment | Likely to have multiple events of sharing needles or injecting equipment with an HIV positive individual or a homosexually active man and has inadequate access to safe injecting equipment |
| AND | |||
| Reported risk in the past 3 months (unless other timeframe stated) | Is a regular sexual partner of an HIV-positive male partner with whom condoms were not consistently used (HIV positive partner is not on treatment and/or has detectable HIV viral load) | Is a regular sexual partner of an HIV-positive man or woman with whom condoms were not consistently used in the last 3 months (HIV positive partner is not on treatment and/or has detectable viral load) | |
| At least one episode of receptive CLAI with any casual HIV-positive male partner or a male partner of unknown HIV status | |||
| A diagnosis of rectal gonorrhoeae, chlamydia and/or syphilis during the last 3 months or at screening | |||
| Has used methamphetamine | |||
| Has had more than one episode of anal intercourse in the last 3 months when proper condom use was not achieved (e.g., condoms slipped off or broke) | |||
| Is uncircumcised and reports more than one episode of insertive CLAI in the last 3 months where the serostatus of their partner was not known, or the partner was HIV positive and not on antiretroviral treatment | |||
| Has been sharing needles or injecting equipment with an HIV positive individual or with a homosexually active man | |||
| Clinicians' discretion | |||
| All people who do not report any of the above risk factors should still be considered at risk of HIV infection and evaluated on a case-by-case basis. | |||
Adapted from National prescribing guidelines (20).